The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in selection of patients with RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC), RET-fusion positive advanced or metastatic thyroid cancer and RET-mutation positive advanced or metastatic medullary thyroid cancer (MTC) who may be eligible for treatment with Lilly’s Retevmo (selpercatinib).
- Read more about Thermo Fisher Scientific gets FDA nod for Oncomine Dx Target Test
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/thermo-fisher-scientific-gets-fda-nod-for-oncomine-dx-target-test
No comments:
Post a Comment